Pros and cons of vaccination against serogroup B meningococcal disease

Area of Science:

• Immunology
• Public Health
• Epidemiology

Background:

• Meningococcal serogroup B is a leading cause of bacterial meningitis.
• A new vaccine against meningococcal B has been approved in the EU.
• Universal infant vaccination is recommended by scientific societies but debated.

Purpose of the Study:

• To discuss the pros and cons of universal vaccination against meningococcal B.
• To analyze the current landscape of meningococcal B vaccine adoption.
• To review cost-effectiveness studies influencing vaccination policy.

Main Methods:

• Literature review of scientific recommendations.
• Analysis of cost-effectiveness studies.
• Comparative review of international vaccination policies.

Main Results:

• The UK is the only Western European country with universal infant vaccination, despite lower incidence than Ireland.
• Other countries like the Czech Republic, Cuba, and regions in Italy have adopted universal vaccination.
• Published cost-effectiveness studies often do not support universal vaccination due to cost-benefit analyses.

Conclusions:

• The decision for universal meningococcal B vaccination involves balancing public health recommendations with economic considerations.
• Divergent adoption strategies highlight the complexity of implementing new vaccine policies.
• Further evaluation is needed to reconcile scientific recommendations with economic feasibility for widespread meningococcal B prevention.